In addition, in the study of Western blot protein evaluation, 8 (72.72%) of the 11 HER-2 positive breast cancer patients were found to have a high expression of caveolin-1 in tumor tissue than in the non-tumor part of the patient (S3 Table). This evidence concerns the gene ERBB2 and neoplasm.